Literature DB >> 1321125

Structure and function of the human platelet thrombin receptor. Studies using monoclonal antibodies directed against a defined domain within the receptor N terminus.

L F Brass1, R R Vassallo, E Belmonte, M Ahuja, K Cichowski, J A Hoxie.   

Abstract

Based upon its recently cloned nucleotide sequence, the human platelet thrombin receptor is thought to be formed by a single polypeptide chain with seven transmembrane domains and an extracellular N terminus that can be cleaved by thrombin. As yet, however, little is known from studies of the receptor protein itself. To obtain such information, we have prepared monoclonal antibodies against a peptide corresponding to receptor residues Ser42 through Phe55, the domain immediately distal to the site of cleavage by thrombin. By flow cytometry, all of the antibodies reacted with the thrombin-responsive megakaryoblastic CHRF-288 and HEL cell lines, but not with the T-lymphoid Sup-T1 cell line. Functionally, the antibodies inhibited platelet responses to alpha-thrombin, gamma-thrombin, and trypsin, but had no effect on platelet activation by ADP, epinephrine, or the thromboxane analog U46619. Radioiodinated antibody bound to approximately 1,800 sites/platelet, a value similar to the reported number of moderate affinity thrombin binding sites per platelet. On Western blots, the antibodies recognized a 66-kDa protein in platelet, HEL, and CHRF-288 membranes. The discrepancy between this apparent size and the predicted mass of the receptor suggests that, as with other G protein-coupled receptors, one or more of the potential sites for N-linked glycosylation have been utilized. Therefore, these results suggest that: 1) the cloned thrombin receptor is involved in a broad range of platelet responses to thrombin, as well as gamma-thrombin and trypsin; 2) as predicted, the N terminus of the receptor is accessible on the platelet surface; 3) the moderate affinity thrombin binding site noted in earlier studies may be the receptor; 4) potentially as much as one third of the mass of the receptor is carbohydrate.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1321125

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

Review 1.  How the protease thrombin talks to cells.

Authors:  S R Coughlin
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin.

Authors:  M L Kahn; M Nakanishi-Matsui; M J Shapiro; H Ishihara; S R Coughlin
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

Review 3.  G-protein-coupled receptors signaling pathways in new antiplatelet drug development.

Authors:  Paul A Gurbel; Athan Kuliopulos; Udaya S Tantry
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-01-29       Impact factor: 8.311

4.  Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity.

Authors:  H Andersen; D L Greenberg; K Fujikawa; W Xu; D W Chung; E W Davie
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

5.  YD-3, a novel inhibitor of protease-induced platelet activation.

Authors:  C C Wu; S W Huang; T L Hwang; S C Kuo; F Y Lee; C M Teng
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 6.  Cellular consequences of thrombin-receptor activation.

Authors:  R J Grand; A S Turnell; P W Grabham
Journal:  Biochem J       Date:  1996-01-15       Impact factor: 3.857

7.  A trypsin-like platelet protease propagates protease-activated receptor-1 cleavage and platelet activation.

Authors:  F A Ofosu; J Freedman; L Dewar; Y Song; J W Fenton
Journal:  Biochem J       Date:  1998-12-01       Impact factor: 3.857

8.  Kallikrein-related peptidase 4: a new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cells.

Authors:  Valérie Gratio; Nathalie Beaufort; Lina Seiz; Josefine Maier; G Duke Virca; Mekdes Debela; Nicolai Grebenchtchikov; Viktor Magdolen; Dalila Darmoul
Journal:  Am J Pathol       Date:  2010-01-07       Impact factor: 4.307

Review 9.  Harnessing the platelet signaling network to produce an optimal hemostatic response.

Authors:  Lawrence F Brass; Maurizio Tomaiuolo; Timothy J Stalker
Journal:  Hematol Oncol Clin North Am       Date:  2013-04-11       Impact factor: 3.722

10.  Tethered ligand-derived peptides of proteinase-activated receptor 3 (PAR3) activate PAR1 and PAR2 in Jurkat T cells.

Authors:  Kristina K Hansen; Mahmoud Saifeddine; Morley D Hollenberg
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.